CORT · Corcept Therapeutics Inc · Webcasts, Transcripts & Audio
$72.94
-0.77 (-1.04%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$7.98B
Shares
109.44M
Volume · Nov 13
1.11M
Avg daily vol (3M)
1.24M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Corcept Therapeutics Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Corcept Therapeutics Inc (CORT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-03
Corcept Therapeutics Inc (CORT) Q3 2026 Earnings Call Transcript
Revenue
$340.47M
▲ 64% YoY Diluted EPS
$1.01
▲ 531.2% YoY Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-07-29
Corcept Therapeutics Inc (CORT) Q2 2026 Earnings Call Transcript
Confident tone
Lifioli (Relacorilant/IBSO) oncology launch
Catalyst and Momentum clinical trial impact
Hyper cortisolism disease awareness / screening
Revenue
$256.15M
▲ 31.7% YoY Diluted EPS
$0.36
▲ 24.1% YoY Gross margin
98.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-30
Corcept Therapeutics Inc (CORT) Q1 2026 Earnings Call Transcript
Confident tone
Hypercortisolism/Cushing's franchise (Korlym)
LeFioli (platinum-resistant ovarian cancer) launch
Revenue guidance and financial outlook
Revenue
$164.90M
▲ 4.9% YoY Diluted EPS
$-0.30
▼ 276.5% YoY Gross margin
98.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Corcept Therapeutics Inc (CORT) Q4 2025 Earnings Call Transcript
Cautious tone
Pharmacy vendor transition disruption
FDA rejection of relacorilant for Cushing's syndrome
Relacorilant oncology program (ROSELLA)
Revenue
$202.12M*
▲ 11.1% YoY Gross margin
98.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Corcept Therapeutics Inc (CORT) Q3 2025 Earnings Call Transcript
Confident tone
Hypercortisolism (Coral) Commercial Growth
Ovarian Cancer / Oncology Pipeline
MASH (MONARCH) and Other Pipeline
Revenue
$207.64M
▲ 13.7% YoY Diluted EPS
$0.16
▼ 61% YoY Gross margin
97.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Corcept Therapeutics Inc (CORT) Q2 2025 Earnings Call Transcript
Confident tone
CATALYST trial and disease awareness
ALS and liver disease pipeline
Ovarian cancer (Rosella/BELLA) program
Revenue
$194.43M
▲ 18.7% YoY Diluted EPS
$0.29
▼ 9.4% YoY Gross margin
98.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Transcript
Confident tone
Hypercortisolism screening expansion and CATALYST study
Relacorilant NDA and launch readiness
Oncology platform (ROSELLA) and broader pipeline
Revenue
$157.21M
▲ 7.1% YoY Diluted EPS
$0.17
▼ 32% YoY Gross margin
98.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Corcept Therapeutics Inc (CORT) Q4 2024 Earnings Call Transcript
Confident tone
Relacorilant NDA and clinical efficacy
CATALYST study and market expansion
ROSELLA ovarian cancer trial
Revenue
$181.89M*
▲ 34.3% YoY Gross margin
98.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Corcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Transcript
Confident tone
Relacorilant NDA submission for Cushing's syndrome
Safety and tolerability of relacorilant
CATALYST Phase 4 trial in difficult-to-control diabetes
Revenue
$182.55M
▲ 47.7% YoY Diluted EPS
$0.41
▲ 46.4% YoY Gross margin
98.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-29
Corcept Therapeutics Inc (CORT) Q2 2024 Earnings Call Transcript
Confident tone
Relacorilant GRACE trial
Korlym commercial growth
CATALYST prevalence study
Revenue
$163.80M
▲ 39.1% YoY Diluted EPS
$0.32
▲ 28% YoY Gross margin
98.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript
Confident tone
Relacorilant GRACE study (Cushing's)
Korlym commercial growth
CATALYST study / hypercortisolism awareness
Revenue
$146.81M
▲ 39% YoY Diluted EPS
$0.25
▲ 78.6% YoY Gross margin
98.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Corcept Therapeutics Inc (CORT) Q4 2023 Earnings Call Transcript
Confident tone
Relacorilant pipeline (GRACE, GRADIENT, NDA)
Korlym franchise and generic entry preparedness
CATALYST Phase 4 prevalence study
Revenue
$135.41M*
▲ 31.4% YoY Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Corcept Therapeutics Inc (CORT) Q3 2023 Earnings Call Transcript
Revenue
$123.60M
▲ 21.5% YoY Diluted EPS
$0.28
▼ 6.7% YoY Gross margin
98.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Corcept Therapeutics Inc (CORT) Q2 2023 Earnings Call Transcript
Revenue
$117.72M
▲ 13.9% YoY Diluted EPS
$0.25
▲ 4.2% YoY Gross margin
98.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Corcept Therapeutics Inc (CORT) Q1 2023 Earnings Call Transcript
Revenue
$105.65M
▲ 12.8% YoY Diluted EPS
$0.14
▼ 30% YoY Gross margin
98.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Corcept Therapeutics Inc (CORT) Q4 2022 Earnings Call Transcript
Revenue
$103.06M*
▲ 4.3% YoY Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Corcept Therapeutics Inc (CORT) Q3 2022 Earnings Call Transcript
Revenue
$101.73M
▲ 5.8% YoY Diluted EPS
$0.30
▲ 25% YoY Gross margin
98.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Corcept Therapeutics Inc (CORT) Q2 2022 Earnings Call Transcript
Revenue
$103.39M
▲ 12.9% YoY Diluted EPS
$0.24
▲ 14.3% YoY Gross margin
98.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Corcept Therapeutics Inc (CORT) Q1 2022 Earnings Call Transcript
Revenue
$93.69M
▲ 17.9% YoY Diluted EPS
$0.20
▲ 11.1% YoY Gross margin
98.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-15
Corcept Therapeutics Inc (CORT) Q4 2021 Earnings Call Transcript
Revenue
$98.82M*
▲ 15.3% YoY Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Corcept Therapeutics Inc (CORT) Q3 2021 Earnings Call Transcript
Revenue
$96.13M
▲ 11.4% YoY Diluted EPS
$0.24
▲ 41.2% YoY Gross margin
98.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Corcept Therapeutics Inc (CORT) Q2 2021 Earnings Call Transcript
Revenue
$91.59M
▲ 3.4% YoY Diluted EPS
$0.21
▼ 8.7% YoY Gross margin
98.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Corcept Therapeutics Inc (CORT) Q1 2021 Earnings Call Transcript
Revenue
$79.44M
▼ 14.8% YoY Diluted EPS
$0.18
▼ 28% YoY Gross margin
98.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-08
Corcept Therapeutics Inc (CORT) Q4 2020 Earnings Call Transcript
Revenue
$85.73M
▼ 2.5% YoY Diluted EPS
$0.20
▼ 16.7% YoY Gross margin
98.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-03
Corcept Therapeutics Inc (CORT) Q3 2020 Earnings Call Transcript
Revenue
$86.33M
▲ 5.9% YoY Diluted EPS
$0.17
▼ 22.7% YoY Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Corcept Therapeutics Inc (CORT) Q2 2020 Earnings Call Transcript
Revenue
$88.56M
▲ 22.6% YoY Diluted EPS
$0.23
▲ 35.3% YoY Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-04
Corcept Therapeutics Inc (CORT) Q1 2020 Earnings Call Transcript
Revenue
$93.25M
▲ 43.8% YoY Diluted EPS
$0.25
▲ 66.7% YoY Gross margin
98.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Corcept Therapeutics Inc (CORT) Q4 2019 Earnings Call
Revenue
$87.89M
▲ 31.5% YoY Diluted EPS
$0.24
▲ 33.3% YoY Gross margin
98.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 webcasts
Key facts
CIK
1088856
CUSIP
218352102
13F (30d)
415 filings
381 filers
Visit website
Investor relations